Skip to main content

Stroke Prevention In Atrial Fibrillation

In Order to Read Online or Download Stroke Prevention In Atrial Fibrillation Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

Stroke Prevention in Atrial Fibrillation

Stroke Prevention in Atrial Fibrillation Book
Author : Greg Flaker
Publisher : Elsevier Health Sciences
Release : 2018-05-24
ISBN : 032355430X
Language : En, Es, Fr & De

GET BOOK

Book Description :

Get a quick, expert overview of stroke risks among patients with treated and untreated atrial fibrillation, in addition to best practices for management and treatment of patients with atrial fibrillation to minimize stroke risks. This concise, clinically-focused resource by Dr. Greg Flaker consolidates today’s available information on this timely topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee cardiologists as well as general practitioners treating and monitoring these patients. Covers a broad spectrum of management and treatment options for atrial fibrillation including anticoagulants, surgical and implanted devices. Presents information on recent drug trials to keep you up to date with the latest developments. Includes guidance on anticoagulation in special situations, such as cardioversion and ablation, in addition to atrial fibrillation treatment in patients with other medical conditions including cancer, major bleeding disorders, and renal or liver disease. Chapter on Risk Stratification assists in identifying patients with a high risk of stroke and predicting treatment outcomes. Chapter on The New Anticoagulation Clinic overviews best practices for patient education, compliance, follow-up monitoring, and quality assurance to aid in better patient outcomes.

Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Current Status Special Situations and Unmet Needs

Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation  Current Status  Special Situations  and Unmet Needs Book
Author : N.A
Publisher :
Release : 2015
ISBN :
Language : En, Es, Fr & De

GET BOOK

Book Description :

In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations, including causing serious bleeding such as intracranial haemorrhage and the need for anticoagulation monitoring. In part related to these limitations, they are used in only about half of patients who should be treated according to guideline recommendations. In the past decade, oral agents have been developed that directly block the activity of thrombin (factor IIa), as well as drugs that directly inhibit activated factor X (Xa), which is the first protein in the final common pathway to the activation of thrombin. These novel non-vitamin K antagonist oral anticoagulants (NOACs) have been shown to be at least as good as warfarin for stroke prevention in atrial fibrillation and they have proved to have better safety profiles. Their net advantage is underscored by significantly lower all-cause mortality compared with warfarin in large clinical trials. Because of these features and their ease of use, they are recommended for stroke prevention in atrial fibrillation. They have also a fast onset and offset of action, but they currently lack specific antidotes. This paper addresses the role of anticoagulation for stroke prevention in atrial fibrillation in the era of NOACs, with a focus on special situations including management in the event of bleeding and around the time of procedures including cardioversion, catheter ablation, and device implantation. Also their use in patients with concomitant coronary artery disease, with advanced age, with chronic kidney disease, or with valvular heart disease will be discussed as well as the interaction of NOACs with other cardiac medication, and switching between anticoagulants.

3 SETTING UP AN AF STROKE PREVENTION SERVICE IN SECONDARY CARE THE SCREENING AND OPTIMISING STROKE PREVENTION IN ATRIAL FIBRILLATION SOS AF SERVICE

3   SETTING UP AN AF STROKE PREVENTION SERVICE IN SECONDARY CARE  THE SCREENING AND OPTIMISING STROKE PREVENTION IN ATRIAL FIBRILLATION  SOS AF  SERVICE Book
Author : Isuru Induruwa
Publisher :
Release : 2017
ISBN :
Language : En, Es, Fr & De

GET BOOK

Book Description :

IntroductionOur work in 2015 showed the burden of AF in acute medical admissions is 15%, a stark contrast to previous literature estimates of 3-6%. Medical inpatients are older with multiple comorbidities and a high stroke-risk (median CHA2DS2VASc score=4.4). 50% of AF patients werenu2019t on anticoagulation on admission and only 38% of newly-diagnosed AF were discharged anticoagulated. MethodsSOS-AF was set up as a secondary-care stroke prevention service at Cambridge University Hospital, UK in October 2017. It provides in-hospital AF screening of all medical admissions, by 2 specialist nurses and 4 stroke clinicians using electronic notes and 12-lead ECG. Every AF patient not on anticoagulation is holistically risk-stratified. Patients/families are involved and educated, and anticoagulation is started where appropriate. We accept referrals from inpatient teams and primary care to our clinic and multidisciplinary meeting. Results In our first year we screened 14979 patients, identifying 393 new AF cases. The AF prevalence was 22.1% in medical admissions. We advised not to anticoagulate 158 patients, where the risks outweighed the benefits. Clinicians followed our advice 82% of the time and 402 patients were appropriately anticoagulated. We have increased local anticoagulation rates by 15% and prevented an estimated 16 cardioembolic strokes and 8 deaths, saving u00a394,600/year on bed-days and the NHS u00a3352,000/year.ConclusionSecondary-care must play an active role in stroke prevention in AF. By cost-effective screening in a high-risk population and providing specialist advice to primary and secondary care, SOS-AF delivers individualised patient care and significant financial savings to the health economy.

Quick Pocket Guide to New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Quick Pocket Guide to New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Book
Author : Luca Masotti,Mario Di Napoli,Daniel A. Godoy,Roberto Cappelli
Publisher : SEEd
Release : 2012-06-05
ISBN : 8897419305
Language : En, Es, Fr & De

GET BOOK

Book Description :

Cardioembolic strokes account for one third of ischemic strokes and atrial fibrillation (AF) representing the main source of this stroke subtype. The rate of stroke is 5%/year in patients with AF. Patients with AF have a 2-7 fold increased risk of stroke compared to patients without. Stroke prevention in atrial fibrillation (SPAF) is therefore of utmost importance and represents a major point in the modern management of AF. This booklet provides an overview of new oral anticoagulants used, listing their pharmacokinetis profile, the evidence of efficacy and their clinical use.

Stroke Prevention

Stroke Prevention Book
Author : Wolfgang Dorndorf,Peter Marx
Publisher : S Karger Ag
Release : 1994
ISBN :
Language : En, Es, Fr & De

GET BOOK

Book Description :

Stroke prevention has proved to be effective in hypertensive patients and those with atrial fibrillation and severe symptomatic carotid stenosis. Various interventional studies, based on knowledge about risk factors and improved methods of identifying stroke etiologies in individuals, have demonstrated that stroke can be avoided in a considerable number of patients. This volume brings together the latest developments in this field and considers future directions. The contributions, written by leading scientists, are organized into sections dealing with classification of strokes, risk factors, secondary prevention in vascular disease, surgical and interventional prevention, and cardioembolic stroke. Each article followed by a detailed summary in German. The book will be a valuable source of information for all those interested in this important subject.

Stroke E Book

Stroke E Book Book
Author : J. P. Mohr,Philip A. Wolf,Michael A. Moskowitz,Marc R Mayberg,Rudiger Von Kummer
Publisher : Elsevier Health Sciences
Release : 2011-05-13
ISBN : 1437737803
Language : En, Es, Fr & De

GET BOOK

Book Description :

First published in 1986 under the editorial direction of Dr. Henry J.M. Barnett, Stroke: Pathophysiology, Diagnosis, and Management continues to provide the dependable, current answers you need to effectively combat the increasing incidence of this disease. Dr. J.P. Mohr, together with new associate editors Philip A. Wolf, James C. Grotta, Michael A. Moskowitz, Marc Mayberg, and Rüdiger von Kummer as well as a multitude of expert contributors from around the world, offer you updated and expanded coverage of mechanisms of action of commonly used drugs, neuronal angiogenesis and stem cells, basic mechanisms of spasm and hemorrhage, prevention of stroke, genetics/predisposing risk factors, and much more, equipping you to understand the latest scientific discoveries and make effective use of the newest approaches to diagnosis and treatment. Gain fresh perspectives and up-to-date insights from the world’s leading authorities on the pathophysiology, diagnosis, and management of stroke. Access the comprehensive, expert clinical guidance you need to recognize the clinical manifestations of stroke, use the latest laboratory and imaging studies to arrive at a diagnosis, and generate an effective medical and surgical treatment plan. Make efficient and accurate diagnoses with the aid of abundant full-color CT images and pathology slides. Stay up to date on hot topics such as mechanisms of action of commonly used drugs, neuronal angiogenesis and stem cells, basic mechanisms of spasm and hemorrhage, prevention of stroke, genetics/predisposing risk factors, and much more.

Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation

Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation   Book
Author : N.A
Publisher :
Release : 2015
ISBN :
Language : En, Es, Fr & De

GET BOOK

Book Description :

Abstract : Abstract: Guidelines recommended oral anticoagulant (OAC) for ischemic stroke patients related to atrial fibrillation (AF). But, underprescription or underdose of warfarin was observed worldwide. We aimed to explore if the use of antithrombotic therapy in nonvalvular AF (NVAF) ischemic stroke patients improved after novel oral anticoagulants (NOACs) became available. Between January 2011 to December 2013, 360 acute ischemic stroke patients related to NVAF were recruited. Patients were categorized into 2 groups based on the date (July 2012) of NOACs' availability. There were 184 patients recruited before July 2012, and whereas 176 patients after July 2012. Demographic data, interested factors, and the percentage of patient on OAC were compared. One month after discharge, percentage of OAC utilization was significantly higher (29% versus 41%; P = 0.022) as well as effective anticoagulation (22.2% versus 80.6%; P

Handbook of Stroke Prevention in Clinical Practice

Handbook of Stroke Prevention in Clinical Practice Book
Author : Karen L. Furie,Peter J. Kelly
Publisher : Springer Science & Business Media
Release : 2004-04-28
ISBN : 1592597696
Language : En, Es, Fr & De

GET BOOK

Book Description :

Despite major advances in the understanding of stroke mechanisms that have occurred over the past quarter century, stroke continues to rank among the leading causes of death and disability worldwide. Although currently it may be difficult to believe, early doubts were expressed as to whether inter ventions in risk factors for either coronary disease or stroke would actually lead to a reduction in the incidence of these disorders. However, large clini cal trials in hypertension, carotid disease, atrial fibrillation, and antithrombotic and antiplatelet therapies have effectively demonstrated the efficacy of these targeted interventions in reducing stroke incidence. More recently, after earlier uncertainty regarding the role of elevated lipids as a risk factor for stroke, clinical trials of the statins have also demonstrated a significant reduction in the incidence of ischemic stroke. However, as em phasized in Handbook of Stroke Prevention in Clinical Practice, despite these gains and the initial decline in stroke incidence that did occur in the 1960s and 1970s, the incidence of stroke disappointingly has failed to show a fur ther significant decline since that time. The editors of Handbook of Stroke Prevention in Clinical Practice raise the very important question of whether recognized strategies for stroke preven tion have been widely or effectively implemented. They correctly empha size the critical importance of identifying the mechanism of stroke in each patient so as to properly direct prevention and treatment. As Dr.

Stroke Prevention

Stroke Prevention Book
Author : John W. Norris,Vladimir Hachinski
Publisher : Oxford University Press
Release : 2001-04-12
ISBN : 0199761116
Language : En, Es, Fr & De

GET BOOK

Book Description :

The treatment of stroke remains ineffective, and prevention is the key issue for this common disease. Norris and Hachinski have recruited an international group of experts to provide a comprehensive, critical review of the evidence on the primary and secondary prevention of cerebrovascular disease and to translate this information into clinical practice. The authors present fresh information on established risk factors such as atrial fibrillation, smoking and hypertension and on new risk factors such as homocysteinemia and the paradoxical role of alcohol. They cover the protective effects of lifestyle changes, diet, exercise, and estrogen. Under secondary prevention, they deal with aspirin, antiplatelet therapy, surgical measures to prevent stroke, angioplasty and stenting, and the importance of cardiac anomalies increasingly revealed by high-definition imaging. While endarterectomy remains controversial for asymptomatic carotid stenosis, it has been clearly defined as the single most effective strategy in secondary prevention. In a concluding section that will be particularly valuable to clinical readers, the authors provide a lucid, balanced discussion of how the findings from clinical trials, where patients are highly selected, closely monitored, and given the highest standard of care, can be effectively applied in the everyday practice of medicine.

Stroke Prevention in Atrial Fibrillation

Stroke Prevention in Atrial Fibrillation Book
Author : N.A
Publisher :
Release : 2016
ISBN :
Language : En, Es, Fr & De

GET BOOK

Book Description :

Atrial fibrillation is found in a third of all ischaemic strokes, even more after post-stroke atrial fibrillation monitoring. Data from stroke registries show that both unknown and untreated or under treated atrial fibrillation is responsible for most of these strokes, which are often fatal or debilitating. Most could be prevented if efforts were directed towards detection of atrial fibrillation before stroke occurs, through screening or case finding, and treatment of all patients with atrial fibrillation at increased risk of stroke with well-controlled vitamin K antagonists or non-vitamin K antagonist anticoagulants. The default strategy should be to offer anticoagulant thromboprophylaxis to all patients with atrial fibrillation unless defined as truly low risk by simple validated risk scores, such as CHA2 DS2 -VASc. Assessment of bleeding risk using the HAS-BLED score should focus attention on reversible bleeding risk factors. Finally, patients need support from physicians and various other sources to start anticoagulant treatment and to ensure adherence to and persistence with treatment in the long term.

Stroke Prevention in Clinical Practice

Stroke Prevention in Clinical Practice Book
Author : Daryll M. Baker
Publisher : Springer Science & Business Media
Release : 2007-12-10
ISBN : 1852339640
Language : En, Es, Fr & De

GET BOOK

Book Description :

This book provides a short clear text to explain how to accurately diagnose a TIA, determine what investigations are indicated and how and when to intervene to reduce the risk of stroke. Short chapters are written in point form with clear diagrams and figures.

Stroke in Atrial Fibrillation An Issue of Cardiac Electrophysiology Clinics

Stroke in Atrial Fibrillation  An Issue of Cardiac Electrophysiology Clinics  Book
Author : Samuel J. Asirvatham
Publisher : Elsevier Health Sciences
Release : 2014-09-05
ISBN : 032328700X
Language : En, Es, Fr & De

GET BOOK

Book Description :

Because atrial fibrillation promotes the formation of blood clots that can travel to the brain and block an artery, atrial fibrillation independently increases the risk of ischemic stroke four-to-five-fold. In this issue expert authors review drug therapies for stroke prevention, use of the new anticoagulants, ablation strategies for stroke prevention, LAA closure for stroke prevention, stroke in heart rhythm device patients, transesophageal echo in atrial fibrillation, and other topics important to the management of this serious complication.

SECONDARY PREVENTION FOR STROKE BY DIRECT ORAL ANTICOAGULANTS DOACS IN PATIENTS WITH ATRIAL FIBRILLATION AND CANCER

SECONDARY PREVENTION FOR STROKE BY DIRECT ORAL ANTICOAGULANTS  DOACS  IN PATIENTS WITH ATRIAL FIBRILLATION AND CANCER Book
Author : Tuyoshi Uesugi
Publisher :
Release : 2017
ISBN :
Language : En, Es, Fr & De

GET BOOK

Book Description :

Background and Aims:Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in cancer survivors. However, it is still unclear about the efficacy and safety of direct oral anticoagulants (DOACs) for prevention in cardioembolic (CE) stroke patients with atrial fibrillation(AF) and cancer.Methods:We extracted the patients with AF and active cancer from consecutive CE stroke 1250 patients treated with DOACs for secondary prevention in our stroke data base from March, 2011 to the April, 2018 and analyzed retrospectivelyResults:The number of the consecutive CE stroke patients which coexisted AF and active cancer was 88(7.0%), interestingly that was significant higher than in non-CE stroke patients with cancer (3%). In CE patients with cancer, the CHADS2 Score was significant lower (3.0u00b11.1) than CE stroke patients without cancer (3.9u00b10.9). In 66.7% of patients with cancer, chemotherapy was carried out, considering the interaction of DOACs and anticancer agents to avoid organ functional disorders. Whereas no significant decline of renal or liver function was observed after chemotherapy, notably, heart failure significantly occurred(34%). Overall, in an observation period (median: 606 days and IQR: 331-1333), Ischemic-stroke was observed in 2.3% of patients with AF and cancer, no intracranial-hemorrhage, no major bleeding, and minor bleeding 4.3%. Mortality was 12.7% (due to a cancer or heart failure).Conclusions:The efficacy and safety of DOACs were suggested in CE stroke patients with AF and cancer. It is important to consider the interaction with the pharmacokinetics of each DOACs with anticancer agents, incorporating the insight of cardio-oncology into the stroke prevention .

Antiplatelet Therapy in ACS and A Fib

Antiplatelet Therapy in ACS and A Fib Book
Author : Victor L. Serebruany,Dan Atar
Publisher : Karger Medical and Scientific Publishers
Release : 2012
ISBN : 3318021687
Language : En, Es, Fr & De

GET BOOK

Book Description :

Written by top experts in the field Platelets play a critical role in the pathophysiology of acute coronary syndromes (ACS) and thromboembolic complications associated with atrial fibrillation. Anticoagulant and antiplatelet therapies are central to the treatment of ACS and atrial fibrillation. Over the last several decades, a better understanding of the pathogenesis of coronary heart disease and atrial fibrillation has led to refinements in antithrombotic strategies and clinical outcomes. With this in mind, some of the issues outlined in this book are new insights in genetic testing and modification of individualized antiplatelet therapy based on rapid bedside platelet analyzers. Most importantly, the current update of pros and cons of novel antiplatelet agents such as prasugrel and ticagrelor are provided in detail. Conventional antiplatelet strategies with aspirin and clopidogrel are also discussed. Special attention is devoted to experimental antiplatelet agents like PAR-1 thrombin receptor antagonists or aptamers. The ability to focus on different diseases beyond ACS, including heart failure and atrial fibrillation, distinguishes this publication. Each chapter was written by top experts in the field and scientists with the utmost authority and expertise to provide cardiologists, internists, and clinical pharmacologists with the latest updates.

Co morbidities in Heart Failure An Issue of Heart Failure Clinics E Book

Co morbidities in Heart Failure  An Issue of Heart Failure Clinics  E Book Book
Author : Faiez Zannad
Publisher : Elsevier Health Sciences
Release : 2014-03-30
ISBN : 0323296955
Language : En, Es, Fr & De

GET BOOK

Book Description :

This issue of Heart Failure Clinics examines co-morbidities in patients with heart failure. Topics include hypertension, diabetes, pulmonary disorders, cardiorenal syndrome, anemia, depression, atrial fibrillation, obesity and cardiac cachexia, peripheral vascular disease, rheumatologic disorders, co-morbidities and polypharmacy, coronary artery disease, and clinical trials.

Stroke Dementia and Atrial Fibrillation

Stroke  Dementia and Atrial Fibrillation Book
Author : Vincenzo Russo,Riccardo Proietti
Publisher :
Release : 2020-09-11
ISBN : 9783039366729
Language : En, Es, Fr & De

GET BOOK

Book Description :

The present special issue will lead you to discover the association between cerebrovascular events, cognitive impairment and atrial fibrillation, through update reviews and original articles exploring the pathophysiological mechanisms underpinning this association and describing the latest results in term of stroke prevention in AF. An interesting scientific journey that reflects the recent advances in pharmacological treatments and interventional procedures involving both mind and heart.

Cardiology E Book

Cardiology E Book Book
Author : Michael H. Crawford,John P. DiMarco,Walter J. Paulus
Publisher : Elsevier Health Sciences
Release : 2009-09-18
ISBN : 0723436444
Language : En, Es, Fr & De

GET BOOK

Book Description :

With your heavy case load, you can't afford to waste time searching for answers. Cardiology, 3rd Edition, by Drs. Crawford, DiMarco, and Paulus, offers you just the practical, problem-based guidance you need to quickly overcome any clinical challenge. 8 color-coded sections cover the 8 major clinical syndromes of cardiovascular disease—each section a virtual "mini textbook" on its topic! 40 new chapters keep you up to date with the latest advances in the field, while more than 2,000 lavish, high-quality illustrations, color photographs, tables, and ECGs capture clinical manifestations as they present in practice. It’s current, actionable information that you can put to work immediately for your patients! Offers a problem-based approach that integrates basic science, diagnostic investigations, and therapeutic management in one place for each cardiovascular disease so you can quickly find all of the actionable knowledge you need without flipping from one section to another. Features introductory bulleted highlights in each chapter that present the most pertinent information at a glance. Presents abundant algorithms to expedite clinical decision making. Includes more than 2,000 lavish, high-quality illustrations, color photographs, tables, and ECGs that capture clinical manifestations as they present in practice, and promote readability and retention. Includes 40 new chapters including Inherited Arrhythmia Syndromes, Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy in CHD, Management of the Cyanotic Patient with CHD, Special Problems for the Cardiology Consultant Dealing with Bariatric/Gastric Bypass — and many more — that equip you with all of the latest knowledge. Presents "Special Problem" sections—many new to this edition—that provide practical advice on problems that can be difficult to treat.

SAFETY AND EFFICACY OF DABIGATRAN FOR SECONDARY STROKE PREVENTION IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION MULTICENTER PROSPECTIVE REGISTRY BY TAIWAN STROKE SOCIETY

SAFETY AND EFFICACY OF DABIGATRAN FOR SECONDARY STROKE PREVENTION IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION MULTICENTER PROSPECTIVE REGISTRY BY TAIWAN STROKE SOCIETY Book
Author : YA-JU LIN
Publisher :
Release : 2017
ISBN :
Language : En, Es, Fr & De

GET BOOK

Book Description :

Background and AimsStroke in nonvalvular atrial fibrillation(NVAF) patients is usually devastating if not adequately prevented. AF patients with stroke are at higher risk of recurrence. Dabigatran, a direct thrombin inhibitor has had been approved as an appropriate preventive option. This multicenter observational prospective cohort study tried to investigate the safety and efficacy of Dabigatran prescribed under routine clinical practice for secondary stroke prevention in NVAF patients.MethodPatients with history of stroke or TIA, started Dabigatran within 3-months of study initiation or after new index-stroke were enrolled. After patientsu2019 consent, we recorded data on their demographics, AF disease information/medical history, laboratory tests and concomitant medications during baseline and follow-up visits. The rate of stroke recurrence, bleeding, gastrointestinal events as well as the drug adherence were evaluated. ResultsFrom Dec 2013 till Apr 2017, 653 patients (M/F:399/254) participated, mean age 71.4u00b110.4, mean follow-up 205 days. The median CHA2DS2VASc score was 5; HAS-BLED scale was 3. Low dose Dabigatran (110 mg BID) was prescribed in 555(85%) patients. Recurrent ischemic stroke was diagnosed in 18 patients/TIA in 2; MI in 5; death in 17 (3%; 0.77 %; 2.6%) (5.45%; 1.36%; 4.6% per year). Hemorrhagic complications were recorded in 46 patients, 56 events (8.6%; 12.5% per year), of which 13 were major bleeding (1.99%; 3.5% per year): intracerebral (3), gastrointestinal (7), genitourinary (2), retroperitoneum (1). Male, ageu226775 y/o were risks of bleeding but no difference between low dose and standard dose. 138 (21.1% ) patients withdrawn prematurely, 37% due to adverse events. ConclusionThe use of low dose Dabigatran in real-world clinical setting among high risk NVAF patients in Taiwan was still associated with comparable efficacy and acceptable safety outcomes.

Difficult Decisions in Clinical Electrophysiology A Case Based Approach An Issue of Cardiac Electrophysiology Clinics E Book

Difficult Decisions in Clinical Electrophysiology   A Case Based Approach  An Issue of Cardiac Electrophysiology Clinics   E Book Book
Author : Mark C. Haigney,Adam Strickberger
Publisher : Elsevier Health Sciences
Release : 2012-10-01
ISBN : 1455745634
Language : En, Es, Fr & De

GET BOOK

Book Description :

This issue consists of 17 case studies, each involving a difficult decision that has to be made in the catheterization laboratory. Reading about the cases and seeing the ECGs will help cardiac electrophysiologists sharpen their clinical skills. The cases are also useful reading for those studying for board certification.

Current Management Guidelines in Thoracic Surgery An Issue of Thoracic Surgery Clinics E Book

Current Management Guidelines in Thoracic Surgery  An Issue of Thoracic Surgery Clinics   E Book Book
Author : M. Blair Marshall
Publisher : Elsevier Health Sciences
Release : 2012-02-28
ISBN : 1455743194
Language : En, Es, Fr & De

GET BOOK

Book Description :

This issue highlights management issues surrounding specific subjects within the clinical practice of thoracic surgery. The articles represent areas of thoracic surgery where there may be controversy, lack of consensus, or evolution. Each author summarizes the available literature with the addition of his or her own personal expertise.